The drugmaker's generic version of drugs such as Harvoni and Epclusa,
which raked in combined sales of $831 million in the quarter ended
June 30, will be launched via a newly created subsidiary Asegua
Gilead's decision comes more than a month after the U.S. Food and
Drug Administration approved Teva Pharmaceutical Industries Ltd's
copycat version of Mylan NV's life-saving allergy injection, EpiPen.
Gilead said the low-cost variants of the drugs will be available at
a list price of $24,000 for the most common course of therapy from
[to top of second column]
U.S. healthcare companies, ranging from insurers to drug retailers,
are stepping up efforts to combat rising drug prices that have been
widely criticized by regulators.
Pharmacy benefits manager Express Scripts Holding Co said http://lab.express-scripts.com/lab/insights/specialty-medications/we-offered-a-path-to-lower-drug-prices-and-gilead-listened
Gilead's move "is a step in the right direction".
(Reporting by Aakash Jagadeesh Babu in Bengaluru)
[© 2018 Thomson Reuters. All rights
Copyright 2018 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.